Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders

Smeland, S ; Muller, C ; Alvegård, Thor LU ; Wiklund, T ; Wiebe, Thomas LU ; Bjork, O ; Stenwig, AE ; Willen, H ; Holmstrom, T and Folleras, G , et al. (2003) In European Journal of Cancer 39(4). p.488-494
Abstract
From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume < 190 ml, 24-h serum methotrexate > 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this... (More)
From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume < 190 ml, 24-h serum methotrexate > 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in > 70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. (C) 2003 Elsevier Science Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prognosis, limb salvage, neo-adjuvant therapy, chemotherapy, osteosarcoma, clinical protocols, sex, Scandinavia
in
European Journal of Cancer
volume
39
issue
4
pages
488 - 494
publisher
Elsevier
external identifiers
  • pmid:12751380
  • wos:000181686800022
  • scopus:12244289913
ISSN
1879-0852
DOI
10.1016/S0959-8049(02)00747-5
language
English
LU publication?
yes
id
bc2f9f66-f327-4910-bc8e-6c111dc98b5d (old id 315438)
date added to LUP
2016-04-01 12:07:29
date last changed
2025-04-04 13:55:58
@article{bc2f9f66-f327-4910-bc8e-6c111dc98b5d,
  abstract     = {{From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume &lt; 190 ml, 24-h serum methotrexate &gt; 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in &gt; 70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. (C) 2003 Elsevier Science Ltd. All rights reserved.}},
  author       = {{Smeland, S and Muller, C and Alvegård, Thor and Wiklund, T and Wiebe, Thomas and Bjork, O and Stenwig, AE and Willen, H and Holmstrom, T and Folleras, G and Brosjo, O and Kivioja, A and Jonsson, Kjell and Monge, O and Saeter, G}},
  issn         = {{1879-0852}},
  keywords     = {{prognosis; limb salvage; neo-adjuvant therapy; chemotherapy; osteosarcoma; clinical protocols; sex; Scandinavia}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{488--494}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders}},
  url          = {{http://dx.doi.org/10.1016/S0959-8049(02)00747-5}},
  doi          = {{10.1016/S0959-8049(02)00747-5}},
  volume       = {{39}},
  year         = {{2003}},
}